1
|
Medeiros M, Candido MF, Valera ET, Brassesco MS. The multifaceted NF-kB: are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors? Cell Mol Life Sci 2021; 78:6161-6200. [PMID: 34333711 PMCID: PMC11072991 DOI: 10.1007/s00018-021-03906-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2021] [Revised: 07/20/2021] [Accepted: 07/23/2021] [Indexed: 12/16/2022]
Abstract
Despite advances in the understanding of the molecular mechanisms underlying the basic biology and pathogenesis of pediatric central nervous system (CNS) malignancies, patients still have an extremely unfavorable prognosis. Over the years, a plethora of natural and synthetic compounds has emerged for the pharmacologic intervention of the NF-kB pathway, one of the most frequently dysregulated signaling cascades in human cancer with key roles in cell growth, survival, and therapy resistance. Here, we provide a review about the state-of-the-art concerning the dysregulation of this hub transcription factor in the most prevalent pediatric CNS tumors: glioma, medulloblastoma, and ependymoma. Moreover, we compile the available literature on the anti-proliferative effects of varied NF-kB inhibitors acting alone or in combination with other therapies in vitro, in vivo, and clinical trials. As the wealth of basic research data continues to accumulate, recognizing NF-kB as a therapeutic target may provide important insights to treat these diseases, hopefully contributing to increase cure rates and lower side effects related to therapy.
Collapse
Affiliation(s)
- Mariana Medeiros
- Department of Cell Biology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Marina Ferreira Candido
- Department of Cell Biology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Elvis Terci Valera
- Department of Pediatrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - María Sol Brassesco
- Department of Biology, Faculty of Philosophy, Sciences and Letters at Ribeirão Preto, FFCLRP-USP, University of São Paulo, Av. Bandeirantes, 3900, Bairro Monte Alegre, Ribeirão Preto, São Paulo, CEP 14040-901, Brazil.
| |
Collapse
|
2
|
Wang M, Li J, Zuo Z, Ren C, Tang T, Long C, Gong Y, Ye F, Wang Z, Huang J. Long non-coding RNA DIO3OS/let-7d/NF-κB2 axis regulates cells proliferation and metastasis of thyroid cancer cells. J Cell Commun Signal 2020; 15:237-250. [PMID: 33058043 DOI: 10.1007/s12079-020-00589-w] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2020] [Accepted: 09/30/2020] [Indexed: 12/12/2022] Open
Abstract
Due to the steadily rising morbidity and mortality, thyroid cancer remains the most commonly seen endocrine cancer. The present study attempted to investigate the mechanism from the perspective of long non-coding RNA (lncRNA) regulation. We identified 53 markedly increased lncRNAs in thyroid cancer samples according to TCGA data. Among them, high lncRNA DIO3OS expression was a risk factor for thyroid cancer patients' poorer overall survival. DIO3OS showed to be considerably increased within thyroid cancer tissue samples and cells. Knocking down DIO3OS within thyroid carcinoma cells suppressed cancer cell viability, the capacity of DNA synthesis, cell invasion, as well as cell migration; besides, proliferating markers, ki-67 and PCNA, were decreased by DIO3OS knockdown. Cancer bioinformatics analysis suggested that NF-κB2 might be related to DIO3OS function in thyroid cancer carcinogenesis. NF-κB2 was positively correlated with DIO3OS, and DIO3OS knockdown decreased NF-κB2 protein levels. Knocking down NF-κB2 within thyroid carcinoma cells suppressed cancer cell viability, the capacity of DNA synthesis, cell invasion, cell migration, and the protein levels of proliferating markers. Let-7d directly targeted DIO3OS and NF-κB2; DIO3OS knockdown upregulated let-7d expression. The overexpression of let-7d suppressed cancer cell viability, the capacity of DNA synthesis, cell invasion, cell migration, as well as the protein levels of proliferating markers. Let-7d inhibition remarkably attenuated the functions of DIO3OS knockdown in NF-κB2 expression and thyroid cancer cell phenotype. In conclusion, DIO3OS/let-7d/NF-κB2 axis regulates the viability, DNA synthesis capacity, invasion, and migration of thyroid cancer cells. The clinical application of this axis needs further in vivo and clinical investigation.
Collapse
Affiliation(s)
- Mingming Wang
- Center for Minimally Invasive Surgery, The Second Xiangya Hospital, Central South University, NO.139, Renmin Middle Road, Furong District, Changsha, Hunan, 410011, People's Republic of China
| | - Jin Li
- Department of Anesthesiology, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China
| | - Zhongkun Zuo
- Center for Minimally Invasive Surgery, The Second Xiangya Hospital, Central South University, NO.139, Renmin Middle Road, Furong District, Changsha, Hunan, 410011, People's Republic of China
| | - Chutong Ren
- Center for Minimally Invasive Surgery, The Second Xiangya Hospital, Central South University, NO.139, Renmin Middle Road, Furong District, Changsha, Hunan, 410011, People's Republic of China
| | - Tenglong Tang
- Center for Minimally Invasive Surgery, The Second Xiangya Hospital, Central South University, NO.139, Renmin Middle Road, Furong District, Changsha, Hunan, 410011, People's Republic of China
| | - Chen Long
- Center for Minimally Invasive Surgery, The Second Xiangya Hospital, Central South University, NO.139, Renmin Middle Road, Furong District, Changsha, Hunan, 410011, People's Republic of China
| | - Yi Gong
- Center for Minimally Invasive Surgery, The Second Xiangya Hospital, Central South University, NO.139, Renmin Middle Road, Furong District, Changsha, Hunan, 410011, People's Republic of China
| | - Fei Ye
- Center for Minimally Invasive Surgery, The Second Xiangya Hospital, Central South University, NO.139, Renmin Middle Road, Furong District, Changsha, Hunan, 410011, People's Republic of China
| | - Zhihong Wang
- Center for Minimally Invasive Surgery, The Second Xiangya Hospital, Central South University, NO.139, Renmin Middle Road, Furong District, Changsha, Hunan, 410011, People's Republic of China
| | - Jiangsheng Huang
- Center for Minimally Invasive Surgery, The Second Xiangya Hospital, Central South University, NO.139, Renmin Middle Road, Furong District, Changsha, Hunan, 410011, People's Republic of China.
| |
Collapse
|
3
|
Marchetti MC, Cannarile L, Ronchetti S, Delfino DV, Riccardi C, Ayroldi E. L-GILZ binds and inhibits nuclear factor κB nuclear translocation in undifferentiated thyroid cancer cells. J Chemother 2020; 32:263-267. [PMID: 32067575 DOI: 10.1080/1120009x.2020.1728862] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Proto-oncogene mutations and abnormal activation of mitogen-activated protein kinase (MAPK) signalling are recurrently found in thyroid cancers. Some thyroid neoplasms respond to drugs that inhibit MAPK pathway activation. Previously, we showed that pharmacological inhibition of MAPK in thyroid cancer cells inhibits cell proliferation and upregulates L-GILZ (long glucocorticoid-induced leucine zipper), a protein with anti-oncogenic and antiproliferative activity, and that L-GILZ is partially responsible for the antiproliferative activity of MAPK inhibitors. Here, we demonstrate that pharmacological inhibition of MAPK in the anaplastic thyroid cancer cell line CAL-62 upregulated L-GILZ, which bound nuclear factor κB (NF-κB) and inhibited its nuclear translocation. These data demonstrate a unique L-GILZ-mediated molecular mechanism that, by trapping NF-κB in the cytoplasm, contributes to the inhibition of proliferation induced by drugs targeting the MAPK transduction cascade. Enhanced knowledge of the mechanism of action of MAPK pathway-inhibiting drugs may improve their clinical use.
Collapse
Affiliation(s)
- Maria Cristina Marchetti
- Department of Medicine, Section of Pharmacology, Medical School, University of Perugia, Perugia, Italy
| | - Lorenza Cannarile
- Department of Medicine, Section of Pharmacology, Medical School, University of Perugia, Perugia, Italy
| | - Simona Ronchetti
- Department of Medicine, Section of Pharmacology, Medical School, University of Perugia, Perugia, Italy
| | - Domenico V Delfino
- Department of Medicine, Section of Pharmacology, Medical School, University of Perugia, Perugia, Italy
| | - Carlo Riccardi
- Department of Medicine, Section of Pharmacology, Medical School, University of Perugia, Perugia, Italy
| | - Emira Ayroldi
- Department of Medicine, Section of Pharmacology, Medical School, University of Perugia, Perugia, Italy
| |
Collapse
|
4
|
Zhao S, Zhao Y, Wang Q, Li Z, Ma X, Wu L, Li W, Du M, Ji H, Qin G. LDOC1 is differentially expressed in thyroid cancer and display tumor-suppressive function in papillary thyroid carcinoma. Cell Biol Int 2020; 44:985-997. [PMID: 31889386 DOI: 10.1002/cbin.11295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2019] [Accepted: 12/27/2019] [Indexed: 11/10/2022]
Abstract
The leucine zipper downregulated in cancer 1 (LDOC1) has been proposed as a regulator of transcription and cell signaling. We have previously demonstrated that LDOC1 is differentially expressed in papillary thyroid carcinoma (PTC), this study was designed to characterize LDOC1 expression in thyroid follicle originated cancer tissues and to specifically evaluate its function in thyroid carcinogenesis. LDOC1 expression was performed in human normal thyroid and thyroid cancer. LDOC1 function was characterized, in two PTC cell lines (TPC1 and BCPAP), through the analysis of in vitro cell proliferation, apoptosis, migration, and invasion along with in vivo tumor xenograft growth. Transduced BCPAP cells were stimulated with tumor necrosis factor α, and the levels of nuclear P65, Bax, Bcl-2, c-Myc, and XIAP were assessed. A luciferase reporter assay was used to measure nuclear factor-κB (NF-κB) activity, and the functional connection between LDOC1 effect and NF-κB activity was determined using a specific NF-κB inhibitor. Our results revealed that LDOC1 was translocated from the nucleus to the cytoplasm in human thyroid cancer, and was significantly downregulated in PTC compared with normal thyroid. LDOC1 overexpression in TPC1 resulted in a significant suppression of the malignant phenotype, whereas LDOC1 ablation in BCPAP promoted this phenotype. Additional studies demonstrated that LDOC1 ablation facilitated nuclear P65 expression and NF-κB activity. NF-κB inhibition reversed the effects of LDOC1 ablation on proliferation, apoptosis, migration, and invasion. Our findings confirmed that LDOC1 is a novel therapeutic target in PTC and provides new insight into the role of LDOC1 in PTC progression, through NF-κΒ signaling suppression.
Collapse
Affiliation(s)
- Shuiying Zhao
- Department of Internal Medicine, Division of Endocrinology, The First Affiliated Hospital of Zhengzhou University, 450000, Zhengzhou, China
| | - Yanyan Zhao
- Department of Internal Medicine, Division of Endocrinology, The First Affiliated Hospital of Zhengzhou University, 450000, Zhengzhou, China
| | - Qingzhu Wang
- Department of Internal Medicine, Division of Endocrinology, The First Affiliated Hospital of Zhengzhou University, 450000, Zhengzhou, China
| | - Zhizhen Li
- Department of Internal Medicine, Division of Endocrinology, The First Affiliated Hospital of Zhengzhou University, 450000, Zhengzhou, China
| | - Xiaojun Ma
- Department of Internal Medicine, Division of Endocrinology, The First Affiliated Hospital of Zhengzhou University, 450000, Zhengzhou, China
| | - Lina Wu
- Department of Internal Medicine, Division of Endocrinology, The First Affiliated Hospital of Zhengzhou University, 450000, Zhengzhou, China
| | - Wen Li
- Department of Internal Medicine, Division of Endocrinology, The First Affiliated Hospital of Zhengzhou University, 450000, Zhengzhou, China
| | - Mengmeng Du
- Department of Internal Medicine, Division of Endocrinology, The First Affiliated Hospital of Zhengzhou University, 450000, Zhengzhou, China
| | - Hongfei Ji
- Department of Internal Medicine, Division of Endocrinology, The First Affiliated Hospital of Zhengzhou University, 450000, Zhengzhou, China
| | - Guijun Qin
- Department of Internal Medicine, Division of Endocrinology, The First Affiliated Hospital of Zhengzhou University, 450000, Zhengzhou, China.,Institute of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, 450000, Zhengzhou, China
| |
Collapse
|
5
|
Ye Y, Zhang L, Song Y, Zhuang J, Wang G, Ni J, Zhang S, Xia W. MicroRNA‑373 exerts anti‑tumor functions in human liver cancer by targeting Rab22a. Mol Med Rep 2019; 20:3874-3882. [PMID: 31485646 DOI: 10.3892/mmr.2019.10600] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2018] [Accepted: 10/12/2018] [Indexed: 11/06/2022] Open
Abstract
Liver cancer is a one of the most frequent types of tumor worldwide. It has long been recognized that microRNAs are important participants in the progression of various types of cancer. The present study explored the role of microRNA‑373 (miR‑373) in liver cancer development. Reverse transcription‑quantitative polymerase chain reaction was performed to evaluate the transcription level of miR‑373 in 96 liver cancer tissues and adjacent normal liver tissues. The association of miR‑373 with clinicopathological characteristics was analyzed using the χ2 test. Kaplan‑Meier univariate analysis and multivariate hazard analysis were performed to identify the clinical potential of miR‑373 in the prognosis of liver cancer patients. Transfection of miR‑373 mimics into Hep3B and HepG2 liver cancer cell lines was conducted to reveal the underlying mechanism in regulating liver cancer progression. The functional assays included proliferation, migration, invasion and luciferase assays. The findings of the present study demonstrated that miR‑373 transcription level was markedly downregulated in liver cancer tissues compared with the adjacent normal tissues and was associated with the clinical prognosis of liver cancer patients. Overexpressing miR‑373 mimics in liver cancer cell lines decreased cell proliferation and invasion, suggesting that miR‑373 exerts anti‑tumor effects in liver cancer. In addition, data from the present study demonstrated the direct effect of miR373 on inhibiting the expression and signaling of Ras‑related protein Rab22a, a well‑known oncoprotein. Taken together, the results from the present study suggested that miR‑373 suppresses liver cancer progression and may serve as a promising prognosis prediction biomarker.
Collapse
Affiliation(s)
- Ying Ye
- Department of Nuclear Medicine, The Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200000, P.R. China
| | - Lijun Zhang
- Department of Nuclear Medicine, The Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200000, P.R. China
| | - Yanan Song
- Department of Nuclear Medicine, The Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200000, P.R. China
| | - Juhua Zhuang
- Department of Nuclear Medicine, The Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200000, P.R. China
| | - Guoyu Wang
- Department of Nuclear Medicine, The Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200000, P.R. China
| | - Jing Ni
- Department of Nuclear Medicine, The Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200000, P.R. China
| | - Suiliang Zhang
- Department of Oncology, The Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200000, P.R. China
| | - Wei Xia
- Department of Nuclear Medicine, The Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200000, P.R. China
| |
Collapse
|
6
|
Pessôa-Pereira D, Medeiros MFDS, Lima VMS, da Silva JC, Cerqueira TLDO, da Silva IC, Fonseca LE, Sampaio LJL, de Lima CRA, Ramos HE. Association between BRAF (V600E) mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series. ARCHIVES OF ENDOCRINOLOGY AND METABOLISM 2019; 63:97-106. [PMID: 30916170 PMCID: PMC10522140 DOI: 10.20945/2359-3997000000120] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/20/2018] [Accepted: 01/14/2019] [Indexed: 12/09/2022]
Abstract
OBJECTIVES We aimed to investigate the prevalence of the BRAF (V600E) mutation in consecutive cases of papillary thyroid carcinoma (PTC) in patients diagnosed and treated at the Hospital Sao Rafael (Salvador, BA, Brazil) and evaluate its association with clinical and pathological characteristics of PTC. SUBJECTS AND METHODS We retrospectively enrolled in the study a total of 43 consecutive PTC patients who underwent total thyroidectomy. We performed DNA extraction from formalin-fixed paraffin-embedded (FFPE) tumour tissue samples. Polymerase chain reaction (PCR) and direct sequencing were used to determine BRAF (V600E) mutation status. Univariate and multivariate logistic regression analyses were employed to identify independent associations. RESULTS The prevalence of BRAF (V600E) mutation was 65.1% (28/43). A high frequency of older patients (p value: 0.004) was observed among the BRAF-mutated PTC group and, in contrast, a low frequency of concurrent Hashimoto's thyroiditis (HT) (p value: 0.011) was noted. Multivariate analysis confirmed that older age (OR: 1.15; 95% CI: 1.00 - 1.33; p value: 0.047) and HT (OR: 0.05; 95% CI: 0.006-0.40; p value: 0.005) were independent factors associated with BRAF (V600E) mutation. CONCLUSION We found a high prevalence of BRAF (V600E) mutation in PTC cases. Older age and no concurrent HT were independently associated with BRAF (V600E) mutation.
Collapse
Affiliation(s)
- Danielle Pessôa-Pereira
- Universidade Federal da BahiaUniversidade Federal da BahiaInstituto de Saúde e CiênciaLaboratório de Estudo da TireoideSalvadorBABrasilDepartamento de Biorregulação, Laboratório de Estudo da Tireoide, Instituto de Saúde e Ciência, Universidade Federal da Bahia (UFBA), Salvador, BA, Brasil
| | - Mateus Fernandes da Silva Medeiros
- Universidade Federal da BahiaUniversidade Federal da BahiaInstituto de Saúde e CiênciaLaboratório de Estudo da TireoideSalvadorBABrasilDepartamento de Biorregulação, Laboratório de Estudo da Tireoide, Instituto de Saúde e Ciência, Universidade Federal da Bahia (UFBA), Salvador, BA, Brasil
| | - Virna Mendonça Sampaio Lima
- Universidade Federal da BahiaUniversidade Federal da BahiaInstituto de Saúde e CiênciaLaboratório de Estudo da TireoideSalvadorBABrasilDepartamento de Biorregulação, Laboratório de Estudo da Tireoide, Instituto de Saúde e Ciência, Universidade Federal da Bahia (UFBA), Salvador, BA, Brasil
| | - Joaquim Custódio da Silva
- Universidade Federal da BahiaUniversidade Federal da BahiaInstituto de Saúde e CiênciaLaboratório de Estudo da TireoideSalvadorBABrasilDepartamento de Biorregulação, Laboratório de Estudo da Tireoide, Instituto de Saúde e Ciência, Universidade Federal da Bahia (UFBA), Salvador, BA, Brasil
| | - Taíse Lima de Oliveira Cerqueira
- Universidade Federal da BahiaUniversidade Federal da BahiaInstituto de Saúde e CiênciaLaboratório de Estudo da TireoideSalvadorBABrasilDepartamento de Biorregulação, Laboratório de Estudo da Tireoide, Instituto de Saúde e Ciência, Universidade Federal da Bahia (UFBA), Salvador, BA, Brasil
| | - Igor Campos da Silva
- Hospital São RafaelDepartamento de Anatomia Patológica e CitopatologiaSalvadorBABrasilDepartamento de Anatomia Patológica e Citopatologia, Hospital São Rafael, Salvador, BA, Brasil
| | - Luciano Espinheira Fonseca
- Hospital São RafaelDepartamento de Anatomia Patológica e CitopatologiaSalvadorBABrasilDepartamento de Anatomia Patológica e Citopatologia, Hospital São Rafael, Salvador, BA, Brasil
- Universidade Federal da BahiaUniversidade Federal da BahiaFaculdade de Medicina da BahiaDepartamento de Anatomia Patológica e Medicina LegalSalvadorBABrasilDepartamento de Anatomia Patológica e Medicina Legal, Faculdade de Medicina da Bahia, Universidade Federal da Bahia (UFBA), Salvador, BA, Brasil
| | - Luiz José Lobão Sampaio
- Hospital São RafaelDepartamento de Medicina NuclearSalvadorBABrasilDepartamento de Medicina Nuclear, Hospital São Rafael, Salvador, BA, Brasil
| | - Cláudio Rogério Alves de Lima
- Hospital São RafaelDepartamento de Cirurgia de Cabeça e PescoçoSalvadorBABrasilDepartamento de Cirurgia de Cabeça e Pescoço, Hospital São Rafael, Salvador, BA, Brasil
| | - Helton Estrela Ramos
- Universidade Federal da BahiaUniversidade Federal da BahiaInstituto de Saúde e CiênciaLaboratório de Estudo da TireoideSalvadorBABrasilDepartamento de Biorregulação, Laboratório de Estudo da Tireoide, Instituto de Saúde e Ciência, Universidade Federal da Bahia (UFBA), Salvador, BA, Brasil
| |
Collapse
|
7
|
Li X, He J, Zhou M, Cao Y, Jin Y, Zou Q. Identification and Validation of Core Genes Involved in the Development of Papillary Thyroid Carcinoma via Bioinformatics Analysis. Int J Genomics 2019; 2019:5894926. [PMID: 31583243 PMCID: PMC6754886 DOI: 10.1155/2019/5894926] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2019] [Accepted: 06/20/2019] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Papillary thyroid carcinoma (PTC) is a common endocrine malignant neoplasm, and its incidence increases continuously worldwide in the recent years. However, efficient clinical biomarkers were still deficient; the present research is aimed at exploring significant core genes of PTC. METHODS We integrated three cohorts to identify hub genes and pathways associated with PTC by comprehensive bioinformatics analysis. Expression profiles GSE33630, GSE35570, and GSE60542, including 114 PTC tissues and 126 normal tissues, were enrolled in this research. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were utilized to search for the crucial biological behaviors and pathways involved in PTC carcinogenesis. Protein-protein interaction (PPI) network was constructed, and significant modules were deeply studied. RESULTS A total of 831 differentially expressed genes (DEGs) were discovered, comprising 410 upregulated and 421 downregulated genes in PTC tissues compared to normal thyroid tissues. PPI network analysis demonstrated the interactions between those DEGs, and top 10 pivotal genes (TGFB1, CXCL8, LRRK2, CD44, CCND1, JUN, DCN, BCL2, ACACB, and CXCL12) with highest degree of connectivity were extracted from the network and verified by TCGA dataset and RT-PCR experiment of PTC samples. Four of the hub genes (CXCL8, DCN, BCL2, and ACACB) were linked to the prognosis of PTC patients and considered as clinically relevant core genes via survival analysis. CONCLUSION In conclusion, we propose a series of key genes associated with PTC development and these genes could serve as the diagnostic biomarkers or therapeutic targets in the future treatment for PTC.
Collapse
Affiliation(s)
- Xiaoyan Li
- 1Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China
| | - Jing He
- 1Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China
| | - Mingxia Zhou
- 2Department of Gastroenterology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
| | - Yun Cao
- 1Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China
| | - Yiting Jin
- 1Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China
| | - Qiang Zou
- 1Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China
| |
Collapse
|
8
|
Xu W, Chen F, Fei X, Yang X, Lu X. Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma. Med Sci Monit 2018; 24:7357-7365. [PMID: 30319138 PMCID: PMC6198713 DOI: 10.12659/msm.910168] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Backgrounds SET and MYND domain-containing protein 2 (SMYD2), which is identified as a protein-lysine methyltransferase, plays a crucial role in the progression of some tumors such as bladder carcinoma. However, the clinical significance of SMYD2 in patients with papillary thyroid carcinoma (PTC) has not been elucidated. In the present study, we aimed to investigate the expression and role of SMYD2 in human PTC. Material/Methods Clinicopathological analysis was performed in 107 patients with PTC. Expression of SMYD2 was determined by immunohistochemistry staining, quantitative RT-PCR, or Western blotting in PTC tissues, adjacent normal tissues, and PTC cells (K1 and B-CPAP). The prognostic value of SMYD2 in PTC patients was assessed by univariate and multivariate analysis. Clinical outcomes were evaluated by Kaplan-Meier log-rank tests. Cell proliferation was examined in PTC cells following overexpression or knockdown of SMYD2. Results SMYD2 was highly expressed in PTC tissues compared to adjacent thyroid tissues. Additionally, high expression of SMYD2 was significantly related to tumor size, lymph node metastasis, and TNM stage. Moreover, SMYD2 was identified as an independent prognosis factor by multivariate analysis. Using 2 PTC cell lines, K1 and B-CPAP, we demonstrated that high expression of SMYD2 can promote tumor cell proliferation. Conclusions SMYD2 expression was upregulated in PTC tissues and significantly related to the poorer prognosis of PTC patients. Our studies suggested the potential role of SMYD2 as a new therapeutic target and prognostic biomarker in human PTC.
Collapse
Affiliation(s)
- Wenchao Xu
- Department of Endocrinology, Yidu Central Hospital of Weifang, Weifang, Shandong, China (mainland)
| | - Fulian Chen
- Department of Endocrinology, Yidu Central Hospital of Weifang, Weifang, Shandong, China (mainland)
| | - Xiao Fei
- Department of Infectious Diseases, Yidu Central Hospital of Weifang, Weifang, Shandong, China (mainland)
| | - Xiaoqing Yang
- Department of Pathology, Qianfoshan Hospital Affiliated to Shandong University, Jinan, Shandong, China (mainland)
| | - Xiaofei Lu
- Department of General Surgery, Jinan Central Hospital of Shandong University, Jinan, Shandong, China (mainland)
| |
Collapse
|
9
|
Zhou D, Li Z, Bai X. BRAF V600E and RET/PTC Promote the Activity of Nuclear Factor-κB, Inflammatory Mediators, and Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Study of 50 Patients in Inner Mongolia. Med Sci Monit 2018; 24:6795-6808. [PMID: 30254191 PMCID: PMC6180901 DOI: 10.12659/msm.909205] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND The aim of this study was to investigate the expression of the BRAF V600E gene mutation and the RET/PTC gene rearrangement in the progression of papillary thyroid carcinoma (PTC) in 50 patients from Inner Mongolia. MATERIAL AND METHODS Clinical data, blood, and tissue samples were obtained from 50 patients with PTC and ten patients with benign thyroid adenoma. Expression of BRAF V600E, RET/PTC, nuclear factor-κB (NF-κB), interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, transforming growth factor (TGF)-β, C-X-C motif chemokine ligand (CXCL)1, CXCL2, C-C motif chemokine ligand (CCL)2, and CCL3 were measured using polymerase chain reaction (PCR), immunohistochemistry, and an enzyme-linked immunosorbent assay (ELISA). RESULTS Of the 50 patients with PTC, 37 patients expressed the BRAF V600E gene mutation, eight patients expressed RET/PTC, and five patients showed concomitant BRAF V600E and RET/PTC. Time to recurrence for patients with PTC with BRAF V600E was significantly increased compared with patients with concomitant BRAF V600E mutation and RET/PTC rearrangement (P<0.05). Expression of BRAF V600E, RET/PTC, and concomitant expression of BRAF V600E and RET/PTC were significantly associated with patient age and lymph node metastasis (P<0.05). Serum levels of NF-κB, IL-1β, IL-6, TNF-α, TGF-β and CCL3, and tumor tissue levels of IL-1β, IL-6, TNF-α, TGF-β, CXCL2 and CCL2 in patients with PTC were significantly increased compared with patients with benign thyroid adenoma, before and after surgery (P<0.05). CONCLUSIONS Expression of the BRAF V600E mutation and RET/PTC translocation promoted the activity of NF-κB, expression of inflammatory mediators, and lymph node metastases in patients with PTC.
Collapse
Affiliation(s)
- Dehua Zhou
- Department of Emergency Surgery, Inner Mongolia Peoples' Hospital, Hohhot, Inner Mongolia, China (mainland).,Department of General Surgery, ZhuJiang Hospital of Southern Medical University, Guangzhou, Guangdong, China (mainland)
| | - Zhou Li
- Department of General Surgery, ZhuJiang Hospital of Southern Medical University, Guangzhou, Guangdong, China (mainland)
| | - Xuefeng Bai
- Department of Emergency Surgery, Inner Mongolia Peoples' Hospital, Hohhot, Inner Mongolia, China (mainland)
| |
Collapse
|
10
|
Fa Z, Min Z, Tang J, Liu C, Yan G, Xi J. MicroRNA-150 suppresses the growth and malignant behavior of papillary thyroid carcinoma cells via downregulation of MUC4. Exp Ther Med 2018; 16:45-52. [PMID: 29896226 PMCID: PMC5995047 DOI: 10.3892/etm.2018.6197] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2017] [Accepted: 11/29/2017] [Indexed: 12/21/2022] Open
Abstract
Previous studies have revealed that microRNA (miR)-150 can act as an oncomiR or a tumor suppressor in numerous types of hematological malignancy and solid tumor. However, the function of miR-150 in papillary thyroid carcinoma (PTC) remains elusive. The present study aimed to investigate the function of miR-150 in PTC and its underlying molecular mechanism. The expression of miR-150 was identified to be significantly downregulated, whereas that of mucin (MUC)4 was significantly upregulated in PTC tissues and cell lines compared with corresponding controls. Further experiments demonstrated that MUC4 is a direct target of miR-150. PTC cell proliferation and capacity for migration and invasion decreased following miR-150 overexpression. It was also demonstrated that miR-150-mediated MUC4 downregulation was associated with an accompanying decrease in human epidermal growth factor receptor 2, as well as its phosphorylated form, resulting in suppressed activation of downstream signaling. In conclusion, the present study demonstrated that miR-150 may serve a key function in suppressing the malignant growth and aggressive behavior of PTC cells through the downregulation of MUC4. These findings may provide a novel approach for diagnostic and therapeutic strategies for PTC.
Collapse
Affiliation(s)
- Zhenzhong Fa
- Department of General Surgery, Wujin Affiliated Hospital of Jiangsu University, Changzhou, Jiangsu 213002, P.R. China.,Department of General Surgery, Changzhou Wujin People's Hospital, Changzhou, Jiangsu 213002, P.R. China
| | - Zhenyu Min
- Department of General Surgery, Wujin Affiliated Hospital of Jiangsu University, Changzhou, Jiangsu 213002, P.R. China.,Department of General Surgery, Changzhou Wujin People's Hospital, Changzhou, Jiangsu 213002, P.R. China
| | - Jianjun Tang
- Department of General Surgery, Wujin Affiliated Hospital of Jiangsu University, Changzhou, Jiangsu 213002, P.R. China.,Department of General Surgery, Changzhou Wujin People's Hospital, Changzhou, Jiangsu 213002, P.R. China
| | - Chuanlei Liu
- Department of General Surgery, Wujin Affiliated Hospital of Jiangsu University, Changzhou, Jiangsu 213002, P.R. China.,Department of General Surgery, Changzhou Wujin People's Hospital, Changzhou, Jiangsu 213002, P.R. China
| | - Guodu Yan
- Department of General Surgery, Wujin Affiliated Hospital of Jiangsu University, Changzhou, Jiangsu 213002, P.R. China.,Department of General Surgery, Changzhou Wujin People's Hospital, Changzhou, Jiangsu 213002, P.R. China
| | - Jianbo Xi
- Department of General Surgery, Wujin Affiliated Hospital of Jiangsu University, Changzhou, Jiangsu 213002, P.R. China.,Department of General Surgery, Changzhou Wujin People's Hospital, Changzhou, Jiangsu 213002, P.R. China
| |
Collapse
|